Brief: Unicycive Initiates Pivotal Clinical Bioequivalence Study Of Renazorb To Treat Hyperphosphatemia
02/06/2022 13:08
June 2 (Reuters) - Unicycive Therapeutics Inc UNCY.O :
* UNICYCIVE INITIATES PIVOTAL CLINICAL BIOEQUIVALENCE STUDY
OF
RENAZORB TO TREAT HYPERPHOSPHATEMIA
Source text for Eikon: ID:nGNX98R8hH
Further company coverage: UNCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss